Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed ... to be at high risk for disease recurrence,” said ...

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

The work was supported by The Mark Foundation for Cancer Research ... VBL Therapeutics, Sankyo and Janssen; and serves on a data safety and monitoring board for Polaris. Smith and Pardoll have ...

The comments mark the latest in a number of trade-related threats unleashed ... home of major drugmakers such as Takeda, ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

The comments mark the latest in a number of trade-related threats unleashed ... home of major drugmakers such as Takeda, Astellas, Daiichi Sankyo and Eisai, which has been expecting strong sales ...

The comments mark the latest in a number of trade-related ... home of major drugmakers such as Takeda, Astellas, Daiichi Sankyo and Eisai, which has been expecting strong sales growth in the ...

The first UK company off the mark was GSK (GSK) after it shelled out $1.15bn (£944mn ... is itself in the frame for important regulatory news this year after the FDA accepted it and Daiichi Sankyo’s ...

The deal with RemeGen gives Seagen a closer rival to AZ and Daiichi Sankyo's Enhertu (trastuzumab ... the drug is predicted to top the $2 billion mark in 2021. Enhertu outperformed Kadcyla at ...